BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-133@catalystbrief.girapphe.com
DTSTAMP:20261117T181602Z
LAST-MODIFIED:20261117T181602Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Readout: Pfizer — PG4 Multivalent Vaccine [Apr 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Assess the Safety\, Tole
 rability\, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conj
 ugate Vaccine Administered to Adults.\nSource: https://clinicaltrials.gov/
 study/NCT07794748\nhttps://catalystbrief.girapphe.com/e/133?lang=en\nNot i
 nvestment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/133?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
